^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® Pan Lung Cancer PCR Panel

    Company:
    Amoy Diagnostics
    Type:
    Other Approval
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [MET exon 14 mutation-Non Small Cell Lung Cancer-gumarontinib]

    Source:
    EClinicalMedicine
    Test:

    AmoyDx® Pan Lung Cancer PCR Panel

    Title:
    Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
    Published date:
    04/06/2023
    Excerpt:
    The single-arm, multicentre, open-label, phase 2 stage of the GLORY study was conducted at 42 centres across China and Japan. Adults with locally advanced or metastatic METex14-positive NSCLC received oral gumarontinib….The objective response rate was 66% (95% CI 54-76) overall (n = 79), 71% (95% CI 55-83) in treatment-naïve patients (n = 44), and 60% (95% CI 42-76) in previously-treated patients (n = 35)....Gumarontinib monotherapy had durable antitumour activity with manageable toxicity in patients with locally advanced or metastatic METex14-positive NSCLC when used in first line or later.
    DOI:
    https://doi.org/10.1016/j.eclinm.2023.101952
    Trial ID:
    GLORY